Research guides

BPC-157: what the research says

Body Protection Compound 157 has a large rodent literature and almost no human data. What the studies measured, in which models, and the caveat behind them.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

BPC-157 has more published animal work behind it than almost any other peptide in this catalogue, and the gap between that literature and what is actually known about the compound in people is correspondingly wide. Both facts matter, and reading one without the other is how the compound gets misdescribed.

What the molecule is

A synthetic chain of fifteen amino acids corresponding to a partial sequence of a protein found in human gastric juice. It is also referred to as Body Protection Compound 157 and, in the clinical development literature, as PL 14736. Its stability in gastric juice is unusual for a peptide and is the property that first drew research attention.

The shape of the literature

The published work clusters around tissue repair — tendon, ligament, muscle and gastrointestinal mucosa — and around cytoprotection, particularly against damage from non-steroidal anti-inflammatory drugs. Mechanistically the recurring themes are angiogenesis, the formation of new blood vessels into damaged tissue, and effects on growth factor receptor expression in fibroblasts.

Almost all of it is rodent work or cell culture. The studies below are representative rather than exhaustive, and each names its model.

The caveat that shapes everything else

A very large proportion of the in-vivo literature on this compound originates from a single research group, and much of it is published in a small number of journals. That is not an accusation of anything; a molecule discovered and championed by one laboratory will naturally have a literature dominated by that laboratory. But independent replication is the mechanism by which a finding becomes established, and a body of work concentrated in one group has had less of it than the raw publication count suggests.

The practical consequence for anyone reading a summary of BPC-157 — including this one — is that the number of supporting papers is a weaker signal here than it would be for a compound studied by many independent groups.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

  1. Chang et al. (2011)Journal of Applied Physiology · 110(3):774–80

    Reported increased outgrowth of tendon fibroblasts from explanted tissue, improved survival under oxidative stress, and increased cell migration.

    in vitro, cultured rat Achilles tendon cells Source

  2. Cerovecki et al. (2010)Journal of Orthopaedic Research

    Reported improved healing of surgically transected medial collateral ligament over 90 days, assessed functionally, biomechanically and histologically.

    rat Source

  3. Brcic et al. (2009)Journal of Physiology and Pharmacology · 60 Suppl 7:191–6

    Examined the compound's effect on angiogenesis during muscle and tendon healing, reporting increased vessel formation at the injury site.

    rat, muscle and tendon injury Source

  4. Novinscak et al. (2008)Surgery Today · 38(8):716–25

    Reported improved recovery of crushed gastrocnemius muscle assessed histologically and functionally against untreated controls.

    rat, muscle crush injury Source

  5. Park et al. (2020)Current Pharmaceutical Design · 26(25):2971–81

    A review of reported cytoprotective activity against NSAID-induced damage, discussing intestinal permeability as the proposed mechanism.

    review of rodent and in vitro work Source

Adverse and null findings reported

Harms, tolerability observations, and trials that did not meet their endpoint. A negative result is a finding and is listed here rather than omitted.

  1. Sikiric et al. (2013)Current Pharmaceutical Design · 19(1):76–83

    A review of NSAID toxicity models in which the compound was assessed as a counteracting agent; reports no toxicity attributable to the peptide itself across the models surveyed, which is a finding from the same research programme rather than an independent safety assessment.

    review of rodent work Source

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

  • No completed randomised controlled trial in humans has been published. Clinical development under the designation PL 14736 did not produce a published phase 3 result, and the compound has no marketing authorisation in any jurisdiction.
  • The absence of reported toxicity in the animal literature comes largely from the same research programme that reports the positive findings. Independent toxicology has not been published at a comparable scale, so an absence of reported harm should not be read as an established safety profile.
  • Long-term effects have not been studied. The animal work is predominantly short-duration injury and repair models measured over days to weeks.
  • Because angiogenesis is among the reported mechanisms, the question of what that means in the presence of existing pathology is an obvious one and has not been addressed in the published work.
  • Study designs differ from each other enough that the results are not directly comparable, and bioavailability in humans has not been established.

Common questions

Has BPC-157 been tested in humans?
Not in a completed and published randomised controlled trial. It entered clinical development as PL 14736 and no phase 3 result has been published. Essentially the entire evidence base is rodent and cell-culture work.
What does the research say BPC-157 does?
Published animal work reports accelerated repair in models of tendon, ligament, muscle and gastrointestinal injury, with angiogenesis and effects on growth factor receptor expression as the recurring proposed mechanisms. Those are findings in rats and in cell culture, and they are not statements about people.
Are there reported side effects of BPC-157?
The animal literature reports no toxicity attributable to the peptide, but that literature comes largely from the research programme that also reports the benefits, and independent toxicology at comparable scale has not been published. An absence of reported harm in that situation is weaker evidence than it appears.
Why is BPC-157 research considered controversial?
Not because the findings are disputed in print, but because so much of the in-vivo work originates from one research group. Independent replication is what turns a finding into an established result, and the publication count here overstates how much of it has happened.
Is BPC-157 approved as a medicine?
No, in any jurisdiction. It is supplied here as a laboratory reagent for in-vitro research, with a certificate of analysis, and not for human or veterinary use.

Compounds covered

The reference page for each compound this article discusses.

Related articles

All guides